MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma

The mitogen‐activated protein kinase (MAPK) pathway plays a central role in colorectal cancers (CRC). In particular, BRAF V600E‐mutant tumors, which represent around 10% of CRCs, are refractory to current therapies. Overexpression and secretion of serine peptidase inhibitor Kazal type 1 (SPINK1) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Räsänen, Kati, Dang, Kien X., Mustonen, Harri, Ho, Tho H., Lintula, Susanna, Koistinen, Hannu, Stenman, Ulf‐Håkan, Haglund, Caj, Stenman, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792734/
https://www.ncbi.nlm.nih.gov/pubmed/29193645
http://dx.doi.org/10.1002/1878-0261.12160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792734/
https://www.ncbi.nlm.nih.gov/pubmed/29193645
http://dx.doi.org/10.1002/1878-0261.12160

Ejemplares similares